Completed PHASE2 INTERVENTIONAL 2-arm NCT00042939

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, With Randomization Between Irinotecan/Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r)

Sponsor: Eastern Cooperative Oncology Group

Conditions Pancreatic Cancer

Interventions cetuximab docetaxel irinotecan hydrochloride

Updated 7 times since 2017 Last updated: Jun 21, 2023 Started: Dec 9, 2003 Primary completion: Jun 30, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer and is currently completed. Eastern Cooperative Oncology Group leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Aug 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Aug 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.